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The vascular endothelium regulates blood flow in response to physiological needs. Endothelial dysfunction is closely related to atherosclerosis
and its risk factors, and it constitutes an intermediate step on the progression to adverse events throughout the natural history of coronary artery
disease (CAD), often affecting clinical outcomes. Understanding the relation of endothelial function with CAD provides an important patho-
physiological insight, which can be useful both in clinical and researchmanagement. In this review,we summarize the current knowledgeon endo-
thelial dysfunction and its prognostic influence throughout thenatural historyofCAD, fromearly atherosclerosis topost-transplantmanagement.
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Introduction
The aim of this review is to provide a summary of the current knowl-
edge on endothelial dysfunction, particularly focused on its clinical
implications in coronary artery disease (CAD). Both coronary and
peripheral endothelial dysfunction will be discussed, as peripheral
endothelial functionoften serves as a surrogate for coronary vascular
function.
The vascular endothelium is a monolayer of cells covering the in-
ternal lumen of all blood vessels, thereby separating the blood
from the vascular wall and organ tissues. The vascular endothelium
serves different functions: (i) it is an anti-coagulant surface1; (ii) it reg-
ulates fluid and molecule traffic between blood and tissues2; (iii) it
contributes to the vascular homeostasis and repair3; (iv) it plays a
crucial role in vascular tone and blood flow regulation.4,5
Cardiovascular risk factors produce endothelial dysfunction by
various complex mechanisms, among which oxidative stress is con-
sidered an important agent. Increased intracellular superoxide pro-
duces endothelial dysfunction by several mechanisms such as NO
inactivation and formation of peroxinitrite, NO synthase uncoupling,
prostacyclin formation inhibition, endothelin expression stimulation,
and a reduced NO signalling due to inhibition of soluble guanylate
cyclase activity.6 All these mechanisms are combined to promote a
vasoconstrictive and pro-coagulantmilieu in endothelial dysfunction.
When endothelial function is altered, any of its functions could be
impaired. Yet, for practical reasons, it is the current standard to
measure endothelial function by the study of its vasomotor regula-
tion function. It is also customary to use the generic term ‘endothelial
function’ as a synecdoche for endothelium-dependent vascular
reactivity.
Sincemyocardial oxygenextraction is very high atbasal conditions,
anyadditionalmetabolic demandsmustbemet byan increase inmyo-
cardial blood supply. In normal conditions, the coronary circulation is
capable of increasing its basal flow by at least three times. This
maximal increase in coronary blood flow is known as coronary
flow reserve (CFR). The main agent in this blood flow regulation is
the coronary endothelium, which produces vasodilator substances
such as nitric oxide (NO) and prostacyclin and vasoconstrictor sub-
stances, mainly endothelin-1, in response to different physiological
stimuli.7 Endothelial shear stress caused by arterial blood flow, and
autacoids such as acetylcholine, histamine, and bradykinin are the
main physiological triggers for endothelium release of NO, which
in turn produces a guanylyl-cyclase-mediated relaxation of vascular
smooth muscle (Figure 1).
However, important, the vascular endothelium is not the only
determinantofcoronarybloodflow.Coronarymicrovascular function
can also be impaired due to other mechanisms as thrombi, debris
embolization, ventricular hypertrophy, myocardial, and vascular
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oedema, smooth muscle dysfunction, etc.7,8 When microvascular
function is impaired by an endothelium-independent factor, CFR is
reduced, limiting the overall vasodilator capacity. Endothelium-inde-
pendent microvascular dysfunction has been shown as a predictor of
adverse cardiovascular events in diverse settings from early athero-
sclerosis9 to post-stenting10,11 and acute myocardial infarction.12
Thus, although the focus of this article is set on the prognostic import-
ance of endothelial dysfunction, it has to be acknowledged thatmicro-
vascular endothelium-independent dysfunction can also be an
important sourceof flowdysregulation and adverse clinical outcomes.
Assessment of endothelial function
There are several ways tomeasure endothelial function in the clinical
setting. Although it is far beyond the scope of this review to discuss
the methodology in detail, we will very briefly summarize the most
common possibilities. For further reading, we refer to recent com-
prehensive reviews.13,14 All the techniques have in common that
they measure the response of the vessels to endothelial-dependent
stimuli, mainly reactive hyperaemia (shear stress) or vasoactive
substances.
The coronary vasomotion can be assessed directly and invasively
by coronary angiography.15–17 In principle, intracoronary vasoactive
stimuli, mainly acetylcholine, are infused to trigger an endothelium-
dependent vascular reaction. A functioning endothelium releases
NO in response to acetylcholine, causing vasodilation in the epicar-
dial arteries and the coronary microcirculation. Epicardial
vasodilation ismeasured by quantitative angiography or intravascular
ultrasound (IVUS); vasodilation in the microcirculation is assessed
measuring the coronary blood flow with a Doppler wire, since the
microcirculation is the main determinant of coronary resistance,
and therefore of coronary blood flow. If the coronary endothelium
is dysfunctional, NO release is deficient, and paradoxical vasocon-
striction, due to direct muscarinic smooth muscle stimulation, is
observed in the epicardial arteries or the microcirculation. Non-
endothelial vasodilation can be measured using other drugs, such
as adenosine or nitroprusside for the microcirculation, and nitrogly-
cerine or nitroprusside for the epicardial arteries. Other non-
pharmacological approaches which have been described for coron-
ary endothelium-dependent vasodilation assessment are based on
flow-mediated dilation (FMD) in response to hyperaemia, like
exercise, mental stress or pacing, or on sympathetic nervous
system activation, like the cold pressor test.
The same principle of FMD can also be applied to the peripheral
vasculature18: Briefly, ultrasound images of the brachial artery are
used to determine arterial diameter before and after reactive
hyperaemia-induced vasodilation. Reactive hyperaemia is achieved
by causing limb ischaemia with a blood pressure cuff for a few
minutes. Flow-mediated dilation is commonly expressed as per
cent change in artery diameter. This technique correlates with inva-
sively measured epicardial coronary function19 and has been widely
used in clinical research.
Peripheral arterial tonometry (PAT) is a newer techniquebasedon
the change in finger pulse wave amplitude in response to reactive
Figure 1 Endothelium-derived vasoactive substances. Shear stress and activation of a variety of receptors leads to a release of nitric oxide by
inducing endothelial nitric oxide synthase. It exerts relaxation of vascular smooth muscle cells and exerts antiproliferative effects as well as inhibits
thrombocyte aggregation and leucocyte adhesion. Other endothelium-derived relaxing factors, including endothelium-derived hyperpolarizing
factor and prostacyclin, are also shown. ACE, angiotensin-converting enzyme; Ach, acetylcholine; AI, angiotensin I; AII, angiotensin II; AT1, angioten-
sin 1 receptor; Bk, bradykinin; COX, cyclooxygenase; ECE, ET-converting enzyme; EDHF, endothelium-derived hyperpolarizing factor; ETA and
ETB, endothelin A and B receptors; ET-1, endothelin-1; L-Arg, L-arginine; M, muscarinic acetylcholine receptor; PGH2, prostaglandin H2; ROS, re-
active oxygen species; S1, serotoninergic receptor; TX, thromboxane receptor; TXA2, thromboxane; 5-HT, serotonin. Reproduced with kind per-
mission from Springer Science and Business Media. Source: Springer. Pflu¨gers Arch- Eur J Physiol (2010) 459:1005–1013. Human endothelial
dysfunction: EDRFs. Flammer and Lu¨scher.101
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hyperaemia.20 A mini-cuff is used on the finger to record pulse amp-
litude, and anotheron thecontralateral arm to serveas acontrol.This
relatively simple technique with a low observer-dependency indeed
correlates with microvascular coronary endothelial function.21
However, the observed reaction is only partly endothelial depend-
ent,22 and other factors affecting the microcirculation, such as the
sympathetic nervous system may affect this measurement.20
Endothelial dysfunction in early
asymptomatic atherosclerosis
The development of atherosclerosis is a continuous process starting
already early in life and has a long asymptomatic initial phase and a
slowprogression caused and acceleratedby the presenceof different
risk factors.23 Importantly, endothelial dysfunction is one of the first
recognizable signs of its development and is present long before the
sometimes-devastating consequences of atherosclerosis appear.
Endothelial dysfunction has been reported in relation with most, if
not all, risk factors for atherosclerosis,24–26 such as hypertension,27
diabetes,28 hyperlipidaemia,29 and ageing.30,31 Endothelial dysfunc-
tion not only is a marker of atherosclerosis but it itself contributes
to the progression of atherosclerosis32 by various mechanisms, by
promoting coagulation, vasoconstriction, and deficient or patho-
logical vascular repair.33 Interestingly, endothelial dysfunction itself
can cause myocardial ischaemia even in the absence of relevant cor-
onary stenosis.34 Thus, it has been proposed that endothelial dys-
function constitutes a first stage of atherosclerosis, summarizing
the influence of all cardiovascular risk factors, and can itself be the
cause of cardiovascular events.35 As endothelial function is asso-
ciated with risk factors, the absence of endothelial dysfunction
might depict a particularly favourable state.36,37
In primary prevention, physicians mainly rely on classical risk
scores (e.g. Framingham or SCORE) to assess the risk for patients.
The measurement of endothelial function, however, as it depicts
the overall burden of risk and includes so far unknown factors,
might be a better measure for re-classification and personalized
decision-making.
For example, Li et al.38 recently showed a worse endothelial func-
tion, as measured by PAT, in patients with the metabolic syndrome
compared with those without it, even though both had the same
number of classical risk factors present. Interestingly, the Northern
Manhattan Study39 prospectively followed 819 subjects during a
mean of 81 months for cardiovascular events, focusing on the incre-
mental predictive value of FMD and its relation to metabolic syn-
drome. Patients with metabolic syndrome had a higher rate of
events (HR: 1.5), but patientswithmetabolic syndromeandendothe-
lial dysfunction had the highest rate (HR: 2.6), which shows an incre-
mental prognostic value of endothelial dysfunction. In type 2 diabetes
a normal peripheral endothelium-dependent vasodilation (as estab-
lished by an FMD .8%) has an excellent negative predictive value
for CAD.37
The cardiovascularHealth Study40 evaluated the relation between
brachial FMD and cardiovascular events in a cohort of 2700 elderly
patientswithout knowncardiovascular disease.Overa5-year follow-
up period, FMD was a predictor of cardiovascular events, even after
adjustment for other risk factors. More recently, the multi-ethnic
study of atherosclerosis (MESA) study, by the same group, proved
the prognostic value of FMD independently of the Framingham
Risk Score in over 3000 patients followed over 5 years.41 Similar
results were obtained in a cohort of 2264 asymptomatic postmeno-
pausal women42 followed up for a mean period of 45 months, in
whom endothelial function was also evaluated by FMD. However,
in other series, as the FATE study43 and the PIVUS study,44 FMD
failed to add incremental prediction value or even correlate with
events (Table 1). However, in the FATE study hyperaemic velocity,
a correlate of microvascular dilation, did correlate with events and
it provided additional independent prognostic value. Methodological
differences and a younger and presumably healthier population in the
FATE study may be accountable for this disparity.
Thus, the presence of endothelial functionmay serve as an import-
ant tool to re-classify the riskof the patients beyond the conventional
risk factors. Future studies thus have to better delineate which
patients benefit most from a measurement and which method is
best to assess endothelial dysfunction.
Endothelial dysfunction in
symptomatic patients without
obstructive coronary artery disease
Over 20% of the patients referred to a coronary angiogram due to
chest pain do not present significant obstructive coronary stenosis.45
Yet, a considerable proportion of these patients suffer from typical
angina, and oftenmyocardial perfusion defects can be demonstrated.
Many of these patients present an abnormal coronary endothelial
function, which can result in chronic ischaemia and facilitate acute
ischaemic events, as explained below.
A study in 27 patients showed howabnormal flow response to se-
lective infusion of acetylcholine in the left anterior descending artery
(LAD) in patients with angina and non-obstructive CADwas related
to concordant exercise-induced myocardial perfusion defects on
SPECT.46 Lerman demonstrated that the perfusion defect could be
provoked at rest using the samemethod of selective LAD acetylcho-
line infusion.34 The results of these two studies show how coronary
vascular dysfunction without severe obstructive disease can be the
source of myocardial ischaemia due to endothelial dysfunction and
the resulting flow dysregulation.
Because the vascular endotheliumnotonly regulates vascular tone
and flow, but has also important roles in vascular permeability and
thrombosis homeostasis, endothelial dysfunction not only may
lead to chronic stable myocardial ischaemia, but can also be the
source atherosclerosis progression32 and acute ischaemic events
(Figures 2). One prospective study from the Mayo Clinic17 in 157
patients with mild CAD, and an invasive coronary endothelial func-
tion test by acetylcholine infusion in the LAD, showed coronary
endothelial dysfunction to be an independent predictor of cardiovas-
cular events. Schachinger et al.47 had similar results in another study
with 147 patients, using the same method. In two other studies
performed in diabetic patients without obstructive CAD, in whom
coronary endothelial function was tested by the cold pressor test,
coronaryendothelial dysfunction showeda correlationwithmyocar-
dial perfusion defects48 and long-term adverse cardiovascular
events.49
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Table 1 Studies of cardiovascular events in patients with endothelial dysfunction and early or stable coronary artery disease
Study Population Number Method Endpoints Results
NOMAS39 Asymptomatic, .40 years old 819 FMD MACE (Stroke + MI + CV death) OR2.89 forpatientswithendothelial dysfunction and
metabolic syndrome; OR 1.64 (NS) for
endothelial dysfunction alone.
Cardiovascular
Health Study40
Asymptomatic, elderly (72–98 years
old)
2792 FMD MACE, heart failure, revascularization, claudication Event free survival at 5 years 78.3 vs. 73.6 (FMD
.median vs. FMD ,median) P ¼ 0.006
MESA41 Asymptomatic 3026 FMD CV death, MI, angina, revascularization, cardiac
arrest, stroke
OR0.79FMD/unit SD;29%correct reclassificationof
risk.
Rossi42 Asymptomatic postmenopausal
women
2264 FMD MACE OR 4.42 for lower FMD tertile vs. higher FMD tertile
FATE43 Healthy, male, low-intermediate FRS 1574 FMD MACE OR 0.92, NS
Papaioannou37 Asymptomatic, type 2 diabetic 75 FMD Nuclear myocardial perfusion imaging FMD.8% had a negative predictive value of 93% for
myocardial ischaemia
PIVUS44 Asymptomatic, over 70 years old 1016 Invasive brachial—
FMD—radial
tonometry
MACE Invasive brachial OR 0.72/SD (P ¼ 0.01). FMD and
tonometry no prognostic value
Framingham third
generation
PAT100
General population, Framingham 3rd
generation
1957 PAT Relation to CV risk factors Correlation with male, BMI, total chol/HDL,
smoking, diabetes, lipid-lowering treatment
Rubinhstein50 Symptomatic; low risk stress tests or
normal coronary angiogram
270 PAT MACE + Revascularization + CV hospitalization Events 48 vs. 28% at 7 years, P ¼ 0.03
Suwaidi17 Symptomatic; no significant coronary
atherosclerosis
157 Direct coronary MI + CV death + heart failure + revascularization Only patients with severe endothelial dysfunction
had events (14%)
Schachinger47 Symptomatic; no stenosis or single
vessel
147 Direct coronary MI + CV death + heart
failure + revascularization + angina + stroke + peripheral
revascularization
Patients with events had significantly poorer vascular
response to acetylcholine
Halcox51 Symptomatic; with and without CAD 308 (132 with CAD; 176
without)
Direct coronary CV death + AMI + unstable angina + stroke Patients with MACE had poorer response, both
micro and macrovascular
Heitzer52 Documented CAD 281 Brachial
plethysmography
CV death, MI, stroke, revascularization Patients with events had lower responses
Nitenberg49 Diabetic patients, no obstructive CAD;
vs. non-diabetic controls
72 diabetics 56 controls Direct coronary, cold
pressor test
Sudden cardiac death, MI, angina, stroke,
TIA, revascularization
Diabetics with abnormal cold pressor test showed
higher MACE rates
E.G
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In symptomatic patients without obstructive CAD, non-invasive
peripheral microvascular endothelial function measured by PAT is
also able to discriminate subjects at high risk for adverse cardiovascu-
lar events.50
Endothelial dysfunction in stable
coronary artery disease
In patients with stable obstructiveCAD, endothelial function is an in-
dependent predictor of symptoms and cardiovascular risk. In one
study, 308 patients with and without CAD were studied by direct
coronary endothelial function testing. Abnormal response to select-
ive intracoronary acetylcholine infusion, both in the epicardial and
microvascular circulation, was an independent predictor of MACE,
even after adjusting for the presence of CAD.51 Another study in
281 patients with documented CAD showed that peripheral endo-
thelial dysfunction also identifies subjects at a higher risk for cardio-
vascular events.52
Diabetic patients constitute a high-risk population for symptomat-
ic and silent myocardial ischaemia. Two substudies of the Detection
of Ischemia in Asymptomatic Diabetics study evaluated the utility of
FMD to predict silent myocardial ischaemia37 and microvascular
damage as expressed by microalbuminuria.53 In these studies, a
cutoff value of 8% FMD showed a high negative predictive value for
silent myocardial ischaemia, and microalbuminuria correlated with
abnormal endothelium-dependent vasoreactivity.
Although endothelial dysfunction is a systemic condition, and thus
non-invasive functional tests correlatewith invasive tests, endothelial
dysfunction in the epicardial arteries can also be focal. One study
showed a correlation between focal endothelial dysfunction and a
larger necrotic core, asmeasuredby IVUS.54 This studyprovides a ra-
tionale for endothelial dysfunction being related to acute coronary
syndrome (ACS). Whether in this case endothelial dysfunction is
the cause or the expression of a vulnerable plaque is uncertain.
Endothelial dysfunction after
coronary artery stenting
Coronary stenting results in acuteendothelial injury, sometimes even
associated with arterial dissection or haematoma, and in the pres-
ence of prosthetic metallic material in the vessel lumen; in the case
of drug-eluting stents (DES), this material is associated with an artifi-
cial polymer and a drug. A functional vascular endothelium prevents
platelet adhesion, aggregation, and activation by the secretion of
prostacyclin and NO, and maintains an adequate balance between
pro-coagulant (tissue factor) and anti-coagulant (heparin, protein
C/S) and thrombolytic factors (tissue plasminogen activator)33; an
injured or dysfunctional endothelium loses its antiplatelet function
and may favour pro-coagulant activity, which in combination with a
reduced blood flow due to vasoconstriction can increase the risk
of stent thrombosis.55
Figure 2 Illustration of the reciprocal interaction between endothelial dysfunction, inflammation and the natural history of coronary artery
disease. Blue arrowsmarkedwith thebox ‘ED’ representprocesses inwhichendothelial dysfunctionmodifies theevolutionorprognosisof coronary
artery disease. Red arrows represent ways in which coronary artery disease contributes to a worse endothelial function.
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Several studies with DES have shown a persistently abnormal
endothelium-dependent vasoreactivity in coronary arteries after
DES implantation (Figure 3). Both the sirolimus56,57 and the pacli-
taxel58 stents exhibit a detrimental effect extending over at least 6
months, while the second-generation zotarolimus stent seems to
have a more benign albeit not neutral behaviour.59 In the study by
Togni, endothelial response was evaluated by bicycle exercise,
while in the rest of the studies the method used was acetylcholine
infusion in the left coronary artery.
The new bioresorbable coronary scaffolds may be promising in
their ability to allow long-term restoration of coronary vasomotion,
especially at the stented segments. Data from theABSORB stent60,61
(a polylactide bioresorbable everolimus-eluting scaffold) showed an
abnormal responseof the segment distal to the scaffold at 12months,
which improved significantly at 24 months; interestingly, the scaf-
folded segments showed improved endothelial-dependent and inde-
pendent vasomotion at 24monthsof implantation,whichwas related
to scaffold degradation assessed by IVUS.
Lim et al. recently showed that in patients who were evaluated in
the catheterization laboratory due to chest pain (in average .1
year after stent placement) coronary vascular function was not
worse than in controls.62 Thus, although it is generally accepted
that coronary endothelial dysfunction may be impaired in the short
term, there might not be long-term relevance. Interestingly,
however, endothelial dysfunction as assessed by brachial FMD has
been reported as a predictor of in-stent restenosis.63
Endothelial dysfunction in acute
coronary syndrome
Most frequently, in ACS there is a local inflammatory status which
affects endothelial function and can make atherosclerotic plaques
more prone to rupture and platelet adhesion, vasospasm, and stasis,
which can precipitate coronary thrombosis.64 Microvascular function
is frequently impaired, but it is uncertain whether this is a contributor
or a consequence of the ACS, and it may be to a large extent endothe-
lial independent, due to thrombi and debris embolization, myocardial
oedema, and other factors. Endothelial function testing is particularly
challenging in ACS. The unpredictable nature of ACS onset, the un-
stable condition of the patient and the early dramatic impairment in
microvascular function, make it very difficult to obtain and interpret
data concerning vascular reactivity in this context.
Coronary endothelial dysfunction seems to be present in most
patients with acute coronary syndrome, and is reversible in a matter
ofmonths.65 In patientswith unstable angina, endothelium-dependent
vasoreactivity parallels inflammatory activity as expressed by
C-reactive protein levels.66
Figure 3 Illustration of the post-stent epicardial reactivity to acetylcholine in the various studies referenced in the text56–62. The values express
the change in coronary artery lumen diameter (%) to acetylcholine or exercise, measured by angiography; horizontal short lines represent average,
and vertical bars standard deviation. The red vertical line separates drug-eluting stents from bare metal stents. As can be appreciated, patients with
drug-eluting stents exhibit a vasoconstrictive response,while patientswith baremetal stents have a roughly neutral vascular response.AEES, absorb-
able everolimus eluting scaffold; BMS, bare metal stent; PES, paclitaxel eluting stent; DES, drug eluting stent; SES, sirolimus eluting stent; ZES, zotar-
olimus eluting stent.
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Endothelial function after ACS, measured in the peripheral circu-
lation, has been shown as an independent predictor of MACE, and
subsequent normalization of endothelial function in these patients
predicts a lower risk of events.67,68 In patients with ST elevation
ACS treated with primary angioplasty, FMD improvement 6
months after the event also correlates with a lower end-diastolic
left ventricular volume.69
Endothelial dysfunction and heart
failure
Diastolic function is most frequently impaired in CAD, as a result of
hypertension, obesity or hypertrophy, but also due to a reduced
NO bioavailability in the myocardium. Nitric oxide plays a role in
myocardial as well as vascular relaxation,70 and there is animal evi-
dence that reduced NO availability due to reactive oxygen species
(ROS) andNOS uncoupling is a causal factor in the development of
diastolic dysfunction.71 In humans with CAD a high prevalence of
diastolic dysfunction has been found, which correlates with endo-
thelial dysfunction as assessed by FMD.72 Myocardial damage in
CAD is frequently not limited to diastolic function, but can lead
to systolic dysfunction due to myocardial necrosis and adverse re-
modelling, and it has already been mentioned how endothelial dys-
function impairs cardiac remodelling after an acute myocardial
infarction.69
Independently of the initial mechanism for heart failure, endothe-
lial dysfunctionplays amajor role in theprogressionof thedisease and
has an important impact on clinical outcomes.73–75 The reduced
stroke volume produces a lower endothelial shear stress, which
causes a dysregulation inNOsynthase isoforms geneexpression,76,77
eventually leading to a reduced NO bioavailability.78 Furthermore,
there is an additional reduction in NO bioavailability caused by
directNOdestruction by ROS,mainly driven by an increase in angio-
tensin II and aldosterone activity, and purine metabolism.79
Both coronary and peripheral endothelial dysfunction have been
found in ischaemic as well as non-ischaemic heart failure patients,80–82
although peripheral endothelial dysfunction, measured by brachial
FMD, seems tobe less important in non-ischaemicpatients,83 suggesting
an incremental role of atherosclerosis in ischaemic patients.
The impaired peripheral endothelium-dependent vasodilation in
response to exercise may limit the oxygen supply to skeletal
muscles and thus have a negative impact on functional class. Periph-
eral endothelial dysfunction in heart failure is related to a worse clin-
ical outcome.73–75 Conversely, regular exercise training has proved
capable of restoring peripheral endothelial vasomotor function in
patients with heart failure,84,85 which is accompanied by a higher ex-
ercise capacity. Thus, the systemic endothelial dysfunction in heart
failure underscores the systemic nature of the disease and may be
used to assess the effectiveness of therapy and predict events.
Endothelial dysfunction inheart failure,measuredbybrachial FMD,
has been shown to be a pre-procedural predictor of good response
to cardiac resynchronization therapy (CRT) in one study. Also, endo-
thelial dysfunction improvement after CRT correlatedwith function-
al improvement.86 Twoother studies have shown thatCRT improves
endothelial dysfunction in heart failure, and that this improvement is
related to an increase in cardiac output, thus probably shear-stress
mediated.87,88 This may be one path by which CRT improves symp-
toms in heart failure.
Endothelial function after heart
transplant
After heart transplant the coronary endothelium is replacedby a pre-
sumably healthier one, stroke volume increases and so does endo-
thelial shear stress, one of the main inducers of NO formation.
However, the restoration of endothelial function is not immediate
or complete, probably due to the persistence of atherosclerosis
risk factors, inflammation and the use of immunosuppressive drugs
such as cyclosporine.
Indeed, a high prevalence of coronary endothelial dysfunction has
been described early after heart transplant.89 Coronary endothelial
dysfunction in early post-transplant patients has been correlated
with a higher risk of developing cardiac allograft vasculopathy
(CAV) as expressed by intimal thickening90 and clinical events.91
When allograft vasculopathy is evident, coronary endothelial dys-
function is the norm.89 Immunosuppression with cyclosporine con-
tributes to the development of endothelial dysfunction in
post-transplant patients through various mechanisms, such as a
decreased synthesis of NO,92 increased levels of endothelin93 and
increased production of ROS.94 Sirolimus seems to have a more
benign effect on endothelial function than cyclosporine.95
The evolution of peripheral endothelial function after heart trans-
plant remains controversial. Although it has been reported to
improve early after transplantation,96 other studies have not con-
firmed thisobservation,97,98 and indeedhave foundahigh andpersist-
ent prevalence of peripheral endothelial dysfunction in the first year
post-transplantation. Peripheral endothelial dysfunction limits the
vasodilator response to exercise, correlates with functional capacity
and may be the cause why heart transplant recipients often do not
achieve a normal functional status.99 Also, it has been found to
correlate with the risk of developing CAV in the first year.97
Conclusion
The assessment of endothelial function provides uswith the ability to
obtain information on the functional significance of cardiovascular
disease at the different stages of the disease. There is a growing
body of evidence to suggest that mainly the non-invasive assessment
may intergrade intoour practice to enable us to classify the riskof the
patients with CAD and assess the success of therapy.
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